Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $11.24, but opened at $12.61. Pharming Group shares last traded at $12.41, with a volume of 3,552 shares trading hands.
Analysts Set New Price Targets
Several brokerages have recently commented on PHAR. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer raised their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th.
Get Our Latest Research Report on PHAR
Pharming Group Price Performance
The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company's fifty day moving average price is $9.27 and its 200 day moving average price is $9.03. The firm has a market capitalization of $812.36 million, a price-to-earnings ratio of -45.93 and a beta of 0.02.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts expect that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
